Christine Barrowclough1, Lynsey Gregg2, Fiona Lobban3, Sandra Bucci2, Richard Emsley4. 1. School of Psychological Sciences, University of Manchester, Manchester, UK; christine.barrowclough@manchester.ac.uk. 2. School of Psychological Sciences, University of Manchester, Manchester, UK; 3. Spectrum Centre, University of Lancaster, Lancaster, UK; 4. Institute of Population Health, University of Manchester, Manchester, UK.
Abstract
BACKGROUND: There are inconsistencies in findings as to whether cannabis use has a negative impact on clinical outcomes for people with established psychosis. Effects may be more evident on patients with recent onset psychosis. AIM: To investigate the relationship between cannabis use and clinical outcome, including whether change in cannabis use affects psychotic symptoms, affective symptoms, functioning and psychotic relapse in a sample of people in early psychosis with comorbid cannabis abuse or dependence. METHODS: One hundred and ten participants were examined prospectively with repeated measures of substance use antecedent to psychopathology at baseline, 4.5, 9, and 18 months. We used random intercept models to estimate the effects of cannabis dose on subsequent clinical outcomes and whether change in cannabis use was associated with change in outcomes. RESULTS: There was no evidence of a specific association between cannabis use and positive symptoms, or negative symptoms, relapse or hospital admissions. However, a greater dose of cannabis was associated with subsequent higher depression and anxiety. Change in the amount of cannabis used was associated with statistically significant corresponding change in anxiety scores, but not depression. Additionally, reductions in cannabis exposure were related to improved patient functioning. CONCLUSIONS: Reducing cannabis may be directly associated with improvements in anxiety and functioning, but not other specific symptoms.
BACKGROUND: There are inconsistencies in findings as to whether cannabis use has a negative impact on clinical outcomes for people with established psychosis. Effects may be more evident on patients with recent onset psychosis. AIM: To investigate the relationship between cannabis use and clinical outcome, including whether change in cannabis use affects psychotic symptoms, affective symptoms, functioning and psychotic relapse in a sample of people in early psychosis with comorbid cannabis abuse or dependence. METHODS: One hundred and ten participants were examined prospectively with repeated measures of substance use antecedent to psychopathology at baseline, 4.5, 9, and 18 months. We used random intercept models to estimate the effects of cannabis dose on subsequent clinical outcomes and whether change in cannabis use was associated with change in outcomes. RESULTS: There was no evidence of a specific association between cannabis use and positive symptoms, or negative symptoms, relapse or hospital admissions. However, a greater dose of cannabis was associated with subsequent higher depression and anxiety. Change in the amount of cannabis used was associated with statistically significant corresponding change in anxiety scores, but not depression. Additionally, reductions in cannabis exposure were related to improved patient functioning. CONCLUSIONS: Reducing cannabis may be directly associated with improvements in anxiety and functioning, but not other specific symptoms.
Authors: C Barrowclough; M Marshall; L Gregg; M Fitzsimmons; B Tomenson; J Warburton; F Lobban Journal: Psychol Med Date: 2014-03-05 Impact factor: 7.723
Authors: L Clausen; C R Hjorthøj; A Thorup; P Jeppesen; L Petersen; M Bertelsen; M Nordentoft Journal: Psychol Med Date: 2013-04-16 Impact factor: 7.723
Authors: Deepak Cyril D'Souza; Edward Perry; Lisa MacDougall; Yola Ammerman; Thomas Cooper; Yu-Te Wu; Gabriel Braley; Ralitza Gueorguieva; John Harrison Krystal Journal: Neuropsychopharmacology Date: 2004-08 Impact factor: 7.853
Authors: Marta Di Forti; Hannah Sallis; Fabio Allegri; Antonella Trotta; Laura Ferraro; Simona A Stilo; Arianna Marconi; Caterina La Cascia; Tiago Reis Marques; Carmine Pariante; Paola Dazzan; Valeria Mondelli; Alessandra Paparelli; Anna Kolliakou; Diana Prata; Fiona Gaughran; Anthony S David; Craig Morgan; Daniel Stahl; Mizanur Khondoker; James H MacCabe; Robin M Murray Journal: Schizophr Bull Date: 2013-12-17 Impact factor: 9.306
Authors: Nora Penzel; Rachele Sanfelici; Linda A Antonucci; Linda T Betz; Dominic Dwyer; Anne Ruef; Kang Ik K Cho; Paul Cumming; Oliver Pogarell; Oliver Howes; Peter Falkai; Rachel Upthegrove; Stefan Borgwardt; Paolo Brambilla; Rebekka Lencer; Eva Meisenzahl; Frauke Schultze-Lutter; Marlene Rosen; Theresa Lichtenstein; Lana Kambeitz-Ilankovic; Stephan Ruhrmann; Raimo K R Salokangas; Christos Pantelis; Stephen J Wood; Boris B Quednow; Giulio Pergola; Alessandro Bertolino; Nikolaos Koutsouleris; Joseph Kambeitz Journal: Schizophrenia (Heidelb) Date: 2022-03-09
Authors: Diego Quattrone; Laura Ferraro; Giada Tripoli; Caterina La Cascia; Harriet Quigley; Andrea Quattrone; Hannah E Jongsma; Simona Del Peschio; Giusy Gatto; Charlotte Gayer-Anderson; Peter B Jones; James B Kirkbride; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Andrea Tortelli; Eva Velthorst; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; Pak C Sham; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Ulrich Reininghaus; Cathryn M Lewis; Robin M Murray; Marta Di Forti Journal: Psychol Med Date: 2020-03-18 Impact factor: 7.723
Authors: Tak Lam Lo; Matthew Warden; Yanling He; Tianmei Si; Seshadri Kalyanasundaram; Manickam Thirunavukarasu; Nurmiati Amir; Ahmad Hatim; Tomas Bautista; Cheng Lee; Robin Emsley; Jose Olivares; Yen Kuang Yang; Ronnachai Kongsakon; David Castle Journal: Asia Pac Psychiatry Date: 2016-06 Impact factor: 2.538
Authors: Rashmi Patel; Robin Wilson; Richard Jackson; Michael Ball; Hitesh Shetty; Matthew Broadbent; Robert Stewart; Philip McGuire; Sagnik Bhattacharyya Journal: BMJ Open Date: 2016-03-03 Impact factor: 2.692